Gene · 1291
COL6A1: collagen type VI alpha 1 chain
12 sourcesgene-search-2026-11-11-0.2.0
Cite this record
ConductScience Library. COL6A1: collagen type VI alpha 1 chain. Genes, record 1291. Release gene-search-2026-11-11-0.2.0, 11 Nov 2026. https://conductscience.org/library/genes/1291
On this page
Gene
Proteins1
Reviewed human proteins whose Swiss-Prot entry states the gene.
| UniProt entry | Protein | Length | Structures | Gene stated in |
|---|---|---|---|---|
| P12109 | Collagen alpha-1(VI) chain | 1,028 | 1 | Ensembl, GeneID, HGNC |
Source UniProt
Patents90
Patents whose sequence listing contains this protein's exact sequence. A patent can list a sequence without claiming it.
| Publication | Published | SEQ ID NO | Protein | Source |
|---|---|---|---|---|
| JP 2026042028 A | 2026-03-10 | 19 | P12109 | Espacenet |
| JP 2026004568 A | 2026-01-14 | 41877 | P12109 | Espacenet |
| EP 4650780 A2 | 2025-11-19 | 8020 | P12109 | Espacenet |
| EP 4641201 A2 | 2025-10-29 | 8134 | P12109 | Espacenet |
| EP 4641203 A2 | 2025-10-29 | 230 | P12109 | Espacenet |
| JP 2025147176 A | 2025-10-06 | 3321 | P12109 | Espacenet |
| JP 2025529142 A | 2025-09-04 | 5961 | P12109 | Espacenet |
| US 12371689 B2 | 2025-07-29 | 5961 | P12109 | Espacenet |
| JP 2025517967 A | 2025-06-12 | 230 | P12109 | Espacenet |
| JP 2025517969 A | 2025-06-12 | 8134 | P12109 | Espacenet |
1 to 10 of 90
See all 90 patentsDrugs2
Drugs a ChEMBL mechanism record says act on the gene's protein, through Open Targets.
Trials66
Trials of those drugs. A trial joins the gene only through a drug that acts on it.
| Trial | Drug | Phase | Results first posted | Source |
|---|---|---|---|---|
| NCT06169319 | COLLAGENASE CLOSTRIDIUM HISTOLYTICUM | PHASE2 | ClinicalTrials.gov | |
| NCT06151197 | COLLAGENASE CLOSTRIDIUM HISTOLYTICUM | PHASE3 | ClinicalTrials.gov | |
| NCT06065436 | COLLAGENASE CLOSTRIDIUM HISTOLYTICUM | ClinicalTrials.gov | ||
| NCT05646602 | COLLAGENASE CLOSTRIDIUM HISTOLYTICUM | ClinicalTrials.gov | ||
| NCT05254457 | COLLAGENASE CLOSTRIDIUM HISTOLYTICUM | PHASE3 | ClinicalTrials.gov | |
| NCT05152173 | COLLAGENASE CLOSTRIDIUM HISTOLYTICUM | PHASE2 | ClinicalTrials.gov | |
| NCT04874870 | COLLAGENASE CLOSTRIDIUM HISTOLYTICUM | PHASE3 | ClinicalTrials.gov | |
| NCT04680156 | COLLAGENASE CLOSTRIDIUM HISTOLYTICUM | ClinicalTrials.gov | ||
| NCT04496167 | COLLAGENASE CLOSTRIDIUM HISTOLYTICUM | PHASE2 | 2023-09-13 | ClinicalTrials.gov |
| NCT04236635 | COLLAGENASE CLOSTRIDIUM HISTOLYTICUM | PHASE2 | 2022-04-12 | ClinicalTrials.gov |
1 to 10 of 66
See all 66 trialsNIH grants1,542
NIH grants whose papers are about the gene, through NIH's grant-paper links.
| Grant | Title | COL6A1 papers | Newest fiscal year |
|---|---|---|---|
| ZIANS003129 | Molecular and Clinical Manifestations of Matrix and Aggregate Myopathies | 34 | 2025 |
| P30CA008748 | Cancer Center Support Grant | 8 | 2025 |
| P30CA016672 | Cancer Center Support Grant | 8 | 2025 |
| P30AR075047 | Skin Biology Resource-Based Center at UCI | 3 | 2025 |
| P30CA062203 | Cancer Center Support Grant | 3 | 2025 |
| P30DK089503 | Michigan Nutrition Obesity Research Center | 3 | 2025 |
| P30ES017885 | Michigan Center on Lifestage Environmental Exposures and Disease (M-LEEaD) | 3 | 2025 |
| P30EY010572 | Ophthalmology Core Facility | 3 | 2025 |
| ZICES102445 | Gene Expression and Microarrays | 3 | 2025 |
| P01AI063302 | The intersection of innate and adaptive immunity to intracellular pathogens | 2 | 2025 |
1 to 10 of 1,542Source NIH's project files
See all 1,542 nih grantsPapers2,357
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Triple-Frequency Electromagnetic Stimulation Combined with Fingolimod Reduces Breast Cancer Cell Proliferation and Metastasis-Associated Extracellular Vesicle Protein Levels. | Pharmaceuticals (Basel) | 2026 | 42797444 | PubTator, text mining | PubMed |
| [Transcriptomic analysis of NT5E/CD73-related macrophage state remodeling in the maternal-fetal immune microenvironment of recurrent pregnancy loss]. | Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi | 2026 | 42750328 | PubTator, text mining | PubMed |
| Type VI collagen is proportionally lower around airways and blood vessels in idiopathic pulmonary fibrosis. | Am J Physiol Cell Physiol | 2026 | 42743047 | PubTator, text mining | PubMed |
| Matrix Architecture and Integrin Branch Balance Distinguish Immune-Regulatory States in Clear Cell Renal Cell Carcinoma. | Curr Issues Mol Biol | 2026 | 42651788 | PubTator, text mining | PubMed |
| Spatial Transcriptomics of Micropapillary, Plasmacytoid, and Sarcomatoid Urothelial Carcinoma Reveals Distinct Molecular Landscapes. | Lab Invest | 2026 | 42641761 | PubTator, text mining | PubMed |
| Nanofibrous Matrices Modulating Glioma Cell Migration and Proliferation and the Exploration of Their Molecular Mechanism. | ACS Appl Bio Mater | 2026 | 42606053 | PubTator, text mining | PubMed |
| The Biological Response of Human NP Cells to Soluble Collagen VI. | Cells | 2026 | 42587749 | PubTator, text mining | PubMed |
| Whole-Exome Sequencing in Undiagnosed Muscular Dystrophies: A High Diagnostic Yield and Novel Insights From Iranian Families. | Hum Mutat | 2026 | 42553504 | PubTator, text mining | PubMed |
| Prednisone, not vamorolone, suppresses novel serum bone and cartilage biomarkers associated with growth failure in children with Duchenne muscular dystrophy. | Sci Rep | 2026 | 42547787 | PubTator, text mining | PubMed |
| Urinary proteomic signature of exercise intolerance in patients at risk of heart failure: evidence from the HOMAGE trial. | EBioMedicine | 2026 | 42531722 | PubTator, text mining | PubMed |
1 to 10 of 2,357
See all 2,357 papersSources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this gene from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/genes/v1/1291
GET https://conductscience.org/api/genes/v1/1291/patents?page=2